Project goal:
The goal of the project is to develop a new drug delivery system based on PEG-PLGA nanoparticles containing Cdc42 inhibitor (CASIN) loaded into a thermosensitive liquid rectal suppository for targeted therapy of colorectal cancer.
Project tasks:
Abstract: Cdc42 is abnormally expressed in colorectal cancer and promotes tumor growth and metastasis. Therefore, Cdc42 is a promising target for targeted cancer therapy. However, commercially available Cdc42 inhibitors have low bioavailability and are rapidly eliminated from the body. In this regard, it is necessary to develop a drug delivery system for small molecules of Cdc42 inhibitors. In this project, we propose to develop a rectal system based on PEG-PLGA nanoparticles loaded with a Cdc42 inhibitor, which can effectively pass through the mucus and deliver the drug to the cells, as a temperature-sensitive gel. It will facilitate the effective distribution and retention of nanoparticles in the intestine.
The goal of the project is to develop a new drug delivery system based on PEG-PLGA nanoparticles containing Cdc42 inhibitor (CASIN) loaded into a thermosensitive liquid rectal suppository for targeted therapy of colorectal cancer.
Project tasks:
- Synthesis and characterization of PEG-PLGA nanoparticles containing a Cdc42 inhibitor
- Evaluation of the effect of PLGA-PEG-CASIN nanoparticles on the viability, migratory and invasive potential of colorectal cancer cells.
- Development and characterization of thermosensitive enemas loaded with PLGA-PEG-CASIN nanoparticles.
- Evaluation of the effect of PLGA-PEG-CASIN nanoparticles loaded into thermosensitive enemas on the viability, migratory and invasive potential of colorectal cancer cells.
- In vivo evaluation of distribution and retention of PLGA-PEG nanoparticles loaded into thermosensitive enemas
Abstract: Cdc42 is abnormally expressed in colorectal cancer and promotes tumor growth and metastasis. Therefore, Cdc42 is a promising target for targeted cancer therapy. However, commercially available Cdc42 inhibitors have low bioavailability and are rapidly eliminated from the body. In this regard, it is necessary to develop a drug delivery system for small molecules of Cdc42 inhibitors. In this project, we propose to develop a rectal system based on PEG-PLGA nanoparticles loaded with a Cdc42 inhibitor, which can effectively pass through the mucus and deliver the drug to the cells, as a temperature-sensitive gel. It will facilitate the effective distribution and retention of nanoparticles in the intestine.